• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma.

作者信息

Squires K E, Rosenkaimer F, Sherwood J A, Forni A L, Were J B, Murray H W

机构信息

Division of Infectious Diseases, Cornell University Medical College, New York, New York.

出版信息

Am J Trop Med Hyg. 1993 May;48(5):666-9. doi: 10.4269/ajtmh.1993.48.666.

DOI:10.4269/ajtmh.1993.48.666
PMID:8390795
Abstract

Twenty-four Kenyan patients with visceral leishmaniasis were treated for 30 days with either conventional therapy (daily pentavalent antimony, n = 14) or experimental immunochemotherapy (daily antimony plus interferon-gamma [IFN-gamma] every other day, n = 10). All 24 patients responded clinically to treatment, and microscopic splenic aspirate scores rapidly decreased in both groups. As judged by splenic aspirate culture results, IFN-gamma-treated patients responded more quickly (50% versus 22% culture-negative after one week and 75% versus 58% culture-negative after two weeks). While not statistically significant, these differences raise the possibility that combination therapy using IFN-gamma, which was safe and well-tolerated, may accelerate the early parasitologic response in patients with visceral leishmaniasis.

摘要

相似文献

1
Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma.
Am J Trop Med Hyg. 1993 May;48(5):666-9. doi: 10.4269/ajtmh.1993.48.666.
2
Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis.用于全身性细胞内感染的免疫化疗:在内脏利什曼病中使用γ干扰素加速反应。
J Infect Dis. 1995 Apr;171(4):992-6. doi: 10.1093/infdis/171.4.992.
3
Immunochemotherapy of visceral leishmaniasis: a pilot trial of sequential treatment with recombinant interferon-gamma and pentavalent antimony.
J Interferon Res. 1993 Feb;13(1):39-41. doi: 10.1089/jir.1993.13.39.
4
Short term treatment of visceral leishmaniasis of the Old World with low dose interferon gamma and pentavalent antimony.低剂量干扰素γ与五价锑对旧大陆内脏利什曼病的短期治疗
Infection. 1993 Nov-Dec;21(6):362-6. doi: 10.1007/BF01728914.
5
Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony.针对细胞内杜氏利什曼原虫感染的免疫化疗:γ干扰素加五价锑。
J Infect Dis. 1988 May;157(5):973-8. doi: 10.1093/infdis/157.5.973.
6
Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma.在印度使用锑剂加γ-干扰素成功治疗难治性内脏利什曼病。
J Infect Dis. 1994 Sep;170(3):659-62. doi: 10.1093/infdis/170.3.659.
7
Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma.
N Engl J Med. 1990 Jan 4;322(1):16-21. doi: 10.1056/NEJM199001043220104.
8
Effect of treatment with interferon-gamma alone in visceral leishmaniasis.单独使用γ-干扰素治疗内脏利什曼病的效果。
J Infect Dis. 1995 Dec;172(6):1627-9. doi: 10.1093/infdis/172.6.1627.
9
Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis.印度内脏利什曼病中对γ干扰素加五价锑的反应
J Infect Dis. 1997 Oct;176(4):1117-9. doi: 10.1086/516526.
10
Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol.
Trans R Soc Trop Med Hyg. 1985;79(5):715-8. doi: 10.1016/0035-9203(85)90200-7.

引用本文的文献

1
Leishmaniasis: where are we and where are we heading?利什曼病:我们在哪里,我们要往哪里去?
Parasitol Res. 2021 May;120(5):1541-1554. doi: 10.1007/s00436-021-07139-2. Epub 2021 Apr 7.
2
Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani.评估针对细胞内杜氏利什曼原虫的宿主和病原体导向治疗的协同作用。
Int J Parasitol Drugs Drug Resist. 2019 Aug;10:125-132. doi: 10.1016/j.ijpddr.2019.08.004. Epub 2019 Aug 21.
3
Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.
细胞因子:内脏利什曼病耐药或疾病进展的关键决定因素:新型诊断和免疫治疗的机会。
Front Immunol. 2019 Apr 5;10:670. doi: 10.3389/fimmu.2019.00670. eCollection 2019.
4
Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.人类免疫缺陷病毒合并感染患者内脏利什曼病的免疫调节治疗
Front Immunol. 2018 Jan 12;8:1943. doi: 10.3389/fimmu.2017.01943. eCollection 2017.
5
Chemotherapeutics of visceral leishmaniasis: present and future developments.内脏利什曼病的化疗药物:现状与未来发展
Parasitology. 2018 Apr;145(4):481-489. doi: 10.1017/S0031182017002116. Epub 2017 Dec 7.
6
Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis.用于宿主导向疗法预防和治疗利什曼病的免疫检查点靶点
Front Immunol. 2017 Nov 8;8:1492. doi: 10.3389/fimmu.2017.01492. eCollection 2017.
7
Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective.从公共卫生角度看印度内脏利什曼病治疗方案的当前挑战
Infect Dis Poverty. 2016 Mar 8;5:19. doi: 10.1186/s40249-016-0112-2.
8
Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.使用封装在乙缩醛化葡聚糖微粒中的AR-12进行宿主介导的杜氏利什曼原虫治疗。
Int J Pharm. 2016 Feb 29;499(1-2):186-194. doi: 10.1016/j.ijpharm.2016.01.004. Epub 2016 Jan 5.
9
Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.免疫疗法和靶向治疗在内脏利什曼病治疗中的应用:现状和未来前景。
Front Immunol. 2014 Jun 26;5:296. doi: 10.3389/fimmu.2014.00296. eCollection 2014.
10
Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.内脏利什曼病的免疫治疗和免疫化学治疗:这种被忽视疾病的有前途的治疗方法。
Front Immunol. 2014 Jun 13;5:272. doi: 10.3389/fimmu.2014.00272. eCollection 2014.